| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 05 Nov 2026 | SCHEDULE 13G/A |
| 04 Nov 2026 |
Form 4: van Houte Hans, Chief Financial Officer
Sold 4,769 shares ($74.6K) |
| 04 Nov 2026 |
Form 4: Ring Christine, Chief Legal Officer
Received 5,786 shares by exercise or conversion ($50.5K) · Sold 10,602 shares ($274K) · Sold 6,113 shares ($158K) |
| 04 Nov 2026 | 144 |
| 03 Nov 2026 | 144 |
| 03 Nov 2026 |
8-K: Other Events
On November 3, 2026, Nurix Therapeutics, Inc. (the “Company”) announced that collaboration partner Sanofi S.A. (“Sanofi”) had notified the Company of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an ... |
| 02 Nov 2026 |
Form 4: van Houte Hans, Chief Financial Officer
Received 10,182 shares by exercise or conversion · Sold 2,834 shares ($74.5K) |
| 02 Nov 2026 |
Form 4: Ring Christine, Chief Legal Officer
Received 10,182 shares by exercise or conversion · Sold 3,957 shares ($104K) |
| 02 Nov 2026 |
Form 4: Hansen Gwenn, Chief Scientific Officer
Received 10,182 shares by exercise or conversion · Sold 3,957 shares ($104K) · Received 1,452 shares by exercise or conversion ($2.7K) · 1 more |
| 02 Nov 2026 | 144 |
| 15 Oct 2026 |
Form 4: Hansen Gwenn, Chief Scientific Officer
Received 1,452 shares by exercise or conversion ($2.7K) · Sold 1,452 shares ($36.3K) |
| 14 Oct 2026 | 144 |
| 14 Oct 2026 |
Form 4: Gregory Julia P, Director
Received 22,583 shares by exercise or conversion ($42K) · Sold 22,583 shares ($529K) |
| 13 Oct 2026 | 10-Q |
| 13 Oct 2026 |
8-K: Results of Operations and Financial Condition
Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL |
| 02 Oct 2026 |
Form 4: Ring Christine, Chief Legal Officer
Received 5,786 shares by exercise or conversion ($50.5K) · Sold 5,786 shares ($134K) |
| 02 Oct 2026 | 144 |
Loading...